Medicare AdvantageCoverageMedium impact
MA08.025h, Omalizumab (Xolair®)
Independence Blue Cross·Allergy & Immunology, Pulmonology, Dermatology·Pharmacy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.025h for Omalizumab (Xolair®) has been reissued with updates effective December 10, 2025. This is a pharmacy policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this specialty biologic medication used primarily for asthma and chronic urticaria.
Action Required
By December 10, 2025: Review the complete updated policy MA08.025h at the provided URL to identify specific changes to Omalizumab (Xolair®) coverage criteria, prior authorization requirements, or billing procedures. Update billing workflows and inform providers of any new requirements for Medicare Advantage patients receiving this medication.